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Abstract
Obesity and morbid obesity are modifiable risk factors for the development and progression of kidney disease. Obesity has
reached epidemic proportions and is currently an important health problem in Europe, so it is necessary to develop
therapeutic and preventive strategies. The obesity-related glomerulopathy has been defined as a secondary form of focal
segmental glomerulosclerosis, and its most characteristic feature is glomerulomegaly. The renal evolution of patients with
obesity-related glomerulopathy (ORG) who have not been treated is unfavourable. However, morbidly obese patients
with ORG that underwent bariatric surgery and drastic weight loss had a better outcome. Many inflammatory factors have
been implicated in the pathogenic mechanism of renal disease in obesity. Hypoadiponectinaemia, hyperleptinaemia
and hyperaldosteronism have been associated with glomerular injury in obese patients. The application of modern
techniques has provided important insights that increase the current understanding of ORG. However, further
investigation is needed.
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The morbid obesity epidemic and its renal
consequences
Obesity has become a worldwide epidemic in the twenty-first
century due to its increasing prevalence in recent decades, as
well as its impacts on morbidity, mortality and quality of life,
and its economic burden. Morbid obesity [body mass index
(BMI) ≥40 kg/m2] is a type of obesity that does not respond to
medical treatment; it requires a surgical approach and its preva-
lence has continued to rise at an alarming rate [1–3]. The distribu-
tion of obesity (BMI ≥30 kg/m2) is not consistent across
geographic regions, and its prevalence in Europe ranges from 4
to 28% in men and from 6.2 to 36.5% in women [1]. The obesity
epidemic, which is the result of combined effects of genetic
predisposition, increased accessibility to high-calorie foods and
decreased physical activity, has led to an increase in the risk
of developing cardiovascular disease, diabetes, dyslipidaemia,
hypertension and/or renal disease. Consequently, in obese
patients, overall cardiovascular morbidity and mortality are
increased [2, 3].
A retrospective cohort study of >320 000 American adultswith
15 and 35 years of follow-up [4] described a strong relationship
between the risk of developing advanced chronic kidney disease
(CKD) and an increased BMI, especially for subjects with a BMI of
>25 kg/m2, regardless of age, sex and race, and the presence of
underlying renal disease, diabetes or hypertension. Similar re-
sults were published 3 years earlier [5] in an epidemiological
study of >9000 American adultswho participated in theNational
Health and Nutrition Examination Survey (NHANES II). In that
study physical inactivity, smoking and morbid obesity were
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found to be risk factors for CKD. Additional studies have shown
that obesity can exacerbate the progression of pre-existing renal
disease [6, 7]. Although the absolute individual risk of develop-
ing CKD is very low for obese individuals [8], there has been in-
creasing interest in obesity as a risk factor for the development
and progression of CKD [9], considering the prevalence of obes-
ity in this patient population. Because obesity is a preventable
risk factor for CKD and because obesity, particularly morbid
obesity, is currently an important health problem in Europe, it
is necessary to develop therapeutic and preventive strategies
[10].
Renal involvement in morbid obesity: a
glomerulopathy with its own entity
Studies of patients with differing degrees of obesity have recog-
nized obesity-related glomerulopathy (ORG) as its own entity
and have defined it as a secondary form of focal segmental glo-
merulosclerosis (FSGS) [11–22]. The most characteristic feature
of ORG is the presence of glomerulomegaly [11–13]. Our working
group first described the presence of early stages of ORG in mor-
bidly obese (MO) patients without overt clinical renal manifesta-
tions who were undergoing open bariatric surgery [11]. The
findings indicated that structural changes primarily involving
the glomerular compartment may be observed in MO patients
before they begin to exhibit significant proteinuria and/or renal
failure. Themost characteristic feature identifiedwas glomerulo-
megaly in >38% of the patients. In most patients, glomerulome-
galy was accompanied by other glomerular lesions. However, in
six patients, glomerulomegaly was the only lesion observed. In
addition, there were high prevalences of increased mesangial
matrix, podocyte hypertrophy, glomerular sclerosis and mesan-
gial cell proliferation. Despite the lack of clinical manifestations,
five of the study patients had already developed FSGS [11]. The
presence of these renal lesions was only associated with the
BMI, and no association with hypertension or hyperglycaemia
was detected, further demonstrating the correlation between
morbid obesity and kidney disease. These findings clarify that
glomerular hypertrophy in patients with morbid obesity is likely
the initial lesion that stimulates podocyte effacement and trig-
gers the inflammatory response eventually resulting in focal seg-
mental glomerulosclerosis. This histological injury leads to the
development of CKD in obese patients. It is therefore important
to identify at-risk patients to prevent or precociously treat obes-
ity-related nephropathy at an early stage and thereby prevent the
development of irreversible CKD. The ‘hyperfiltration theory’ is
also thought to be involved in the progression to end-stage
renal disease, although in the presence of normal renal mass
this mechanism is not completely understood [23]. However,
not all MO patients develop ORG, implicating the importance of
genetic susceptibility and environmental conditions in its devel-
opment. Apparently, it seems to be a subgroup of obese patients
with a unique phenotype, themetabolically healthy obesity, that
does not associate higher risk of incident CKD [24, 25]. Although
the incidence of ORG is unknown due to a lack of data in the lit-
erature, D’Agathi and co-workers [13, 26] observed an alarming
increase in its incidence in a retrospective study of patients
with proteinuria or proteinuria and renal failure performed
between 1986 and 2000. Recent data from the same group showed
further rise in the incidence of ORG between 2001 and 2015 (from
2 to 2.7%) [26]. These findings are consistent with the increasing
prevalence of obesity in the general population during this
period.
Clinical manifestations and evolution of
obesity-related glomerulopathy
The degree of kidney function in obesity nephropathy depends
on the time of its determination. It is not uncommon to detect
glomerular hyperfiltration at the time of onset of renal injury as
occurs in patients with diabetes mellitus [27–29]. This hyperfil-
tration decreases when patients undergo drastic weight loss
[29–31]. Once renal injury occurs, glomerular hyperfiltration can
be observed in addition to apparently normal renal function or
renal function deterioration. The initial clinical feature of renal
injury is the presence of albuminuria or proteinuria [4, 28–30].
Both of these conditions may precede a decrease in renal
function by several years, as occurs in diabetes. Proteinuria and
albuminuria develop in 10–41% [4, 28, 32] and in 12–43% [28–34]
of obese patients, respectively. In addition, some studies have de-
scribed the presence of microhaematuria in 5–26% of patients
with differing degrees of obesity [4, 29]. In contrast, proteinuria
in obese patients can be of low grade or have levels of nephrotic
range and it is not usually accompanied by oedema, hypoalbumi-
naemia or severe hyperlipidaemia [13]. The renal evolution of
patients with ORG and clinical proteinuria or renal failure who
have not been treated is unfavourable in those with FSGS and
in those with glomerulomegaly alone [13, 35]. Different studies
have reported variable renal survival rates, a rate of 60% at
8 years of follow-up has been reported in a study by Kambham
et al. [13] and rates of 77 and 51% at 5 and 10 years, respectively,
have been described in a study by Praga et al. [35]. Nevertheless, a
comparison of the survival curves between idiopathic FSGS and
FSGS secondary to obesity revealed that the latter was associated
with better prognosis [13]. In our experience, the long-term renal
outcome of patientswith ORGwith normal renal function orwith
or without proteinuria is very good (10 years) if they undergo bar-
iatric surgery and drastic weight loss [36].
Obesity as a state of chronic inflammation
Adipose tissue is not inert; rather, it is considered a true
endocrine organ that produces bioactive substances that directly
influence insulin resistance and vascular injury. The dysregula-
tion of these factors mediates the pathogenesis of obesity
comorbidities [37, 38]. In addition, the identification of some
genes responsible for obesity has increased the understanding
of how the body deals with disturbances in the energy balance
[39, 40]. Leptin is a product of the ob gene, and it is synthesized
mainly in adipose tissue of obese patients in whom the plasma
level is elevated so that these increased leptin levels are propor-
tional to the amount of adipose tissue. Thus, when there is an
increase in intake accompanied by a decrease in energy expend-
iture, adipocyte size increases, resulting in increases in both the
synthesis and release of leptin. Despite these increased levels,
obese patients typically exhibit resistance to leptin; however,
the mechanisms through which this occurs are unknown [39].
Furthermore, the kidneys contain a leptin receptor that is present
mainly in the renal medulla. Because this receptor belongs to the
family of class I cytokine receptors, it is thought that leptin may
have an important role in inflammatory kidney disorders such as
obesity [37]. Although the functions of leptin receptor in the kid-
neys are unknown, experimental studies have demonstrated that
leptin exerts a fibrogenic effect by increasing the expression of
glomerular transforming growth factor-β1, and that this effect
is associated with the appearance of proteinuria [41]. In addition,
leptin acts on the renal tubules by increasing the tubular re-
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filtration through tubuloglomerular feedback. This glomerular
hyperfiltration mechanism has also been implicated for other
molecules, such as insulin, angiotensin II and aldosterone [27,
42, 43]. Although leptin and adiponectin exert beneficial effects
on energy balance by promoting sensitivity to insulin,
increased leptin levels and decreased adiponectin levels may
have deleterious effects on the kidneys. Obesity is associated
with hypoadiponectinaemia,which has been linked to insulin re-
sistance, cardiovascular disease and glomerular injury [44, 45].
Reduction in adiponectin levels appears to be regulated by
fetuin-A, which is a glycoprotein synthesized in the liver that
promotes insulin resistance, among other functions. Obese indi-
viduals have increased levels of fetuin-A, which promotes a
down-regulation of adiponectin synthesis by the adipocytes.
Both excess caloric intake and decreased adiponectin reduce
the activation of an energy sensor that is present in liver cells
and podocytes (5′-AMP activated protein kinase), thereby pro-
moting podocyte effacement and albuminuria [44].
Experimental studies have demonstrated [45] that adiponec-
tin deficiency in mice is associated with podocyte effacement
and fusion, as has been observed in some patients with obesity
and morbid obesity [12, 28]. These changes are accompanied by
albuminuria and do not occur in mice with no such deficit. The
administration of adiponectin to mice reduces podocyte damage
and leads to the partial resolution of albuminuria [45].
In our previous study, we found that patients with morbid
obesity and early stages of ORG had an increased leptin level
and a decreased adiponectin level comparedwith normal-weight
controls [28]. The drastic weight loss that occurred in patients
who underwent bariatric surgery helped to reduce leptin levels
and increase adiponectin levels, which were accompanied by
a decreased albuminuria [28]. Therefore, all of the mechanisms,
includingweight loss, that contributed to decreasing leptin levels
and increasing adiponectin levels helped to prevent or improve
obesity-related renal injury. Another adipokine with an in-
creased level in obesity is aldosterone. This increase can occur
independently or as part of the renin–angiotensin axis and may
contribute to the development of ORG through twomechanisms:
by promoting glomerular hyperfiltration via tubuloglomerular
feedback (similar to leptin) or by direct injury of podocytes due
to the production of reactive oxygen species [46]. Spontaneously
hypertensive rats with a spontaneous mutation in the gene
encoding leptin receptor were compared with a group of rats
without this mutation. In the spontaneous evolution of the
mutated rats, they developed obesity, which did not occur in
the rats without the mutation. Parallel to the development
of obesity and proteinuria, podocyte alterations appeared. The
aldosterone levels were measured, revealing increased levels in
the obese rats. When an inhibitor of aldosterone (eplerenone)
was administered, reduction in podocyte damage was observed,
accompanied by decreased proteinuria [46]. In patients with
obesity, central fat is associatedwith increased risks ofmorbidity
and mortality [9, 47], especially in men. In fact, central obesity is
themost important factor that predisposes individuals to insulin
resistance and hyperinsulinaemia, thus favouring the develop-
ment of type 2 diabetes mellitus [48–50]. Notably, Fontana et al.
[50] published an interesting study on 25MO patients. High levels
of adipokines were observed in the portal vein, and these levels
were compared with those in the peripheral blood. The findings
suggested that visceral adipose tissue is the largest producer of
interleukin-6 (IL-6), thus confirming the association between vis-
ceral fat and systemic inflammation in patients with morbid
obesity [50]. In a study conducted by our group with MO patients
with normal renal function and early stages of ORG, we found
that BMI was correlated with IL-6 plasma concentration. How-
ever, we did not observe any relationships between the plasma
levels of inflammatory mediators and glomerular lesions [51].
Many other factors related to inflammation in obesity have
been studied recently. Despite various attempts to elucidate the
pathogenic mechanisms of renal disease in obesity, most of
which have been experimental, there is still a lack of knowledge
on this subject, and further investigation is needed. Only a few
studies have reported associations among obesity, renal injury
and inflammatory hormones [51–53]. Insulin-like growth hor-
mone-1 (IGF-1) levels are decreased in obesity [54, 55]. We have
recently identified a link between a low IGF-1 hormone level
and the presence of renal injury in MO patients with early stages
of ORG [53]. Additionally, IGF-1 gene expression has been shown
to be decreased in kidney biopsies from MO patients with early
stages of ORG compared with those from a normal-weight con-
trol group (M. Navarro, unpublished data), whereas expression
of the proinflammatory genes IL-6 and glucose transporter-1
was increased (M. Navarro, unpublished data). Wu et al. [52]
have previously demonstrated the differential expression of
genes related to inflammatory cytokines, lipidmetabolism and in-
sulin resistance in kidney biopsies from obese patients with pro-
teinuria and ORG. This altered gene expression was not observed
in biopsies from kidney donors. These findings indicate the exist-
ence of a cause–effect relationship of lipid dysmetabolism, insulin
resistance and activation of an inflammatory process with the de-
velopment of obesity-related glomerulopathy.
Thus, these results provide important insights that increase
the current understanding of ORG. The application of modern
techniques, such as genomic techniques, might be useful to
open new avenues for further investigation.
Therapeutic approach
It is justifiable to consider that if obesity is amodifiable risk factor
for kidney disease, then developing the first therapeutic inter-
vention to prevent obesity, given its high prevalence, should be
a public health priority. By preventing obesity, a high percentage
of all CKD cases in industrialized countries might be prevented
[56, 57]. For patients who are already obese, an effective treat-
ment should be established to promoteweight loss and thus pre-
vent or treat its comorbidities, such as CKD. There is increasing
evidence thatweight loss not only helps to reduce glomerular hy-
perfiltration and proteinuria [28–30, 34, 58–62] but also attenuates
metabolic disorders associated with obesity, such as hyperten-
sion [28, 29, 58, 63], altered lipid metabolism [28, 29], insulin re-
sistance and inflammation [28]. Few studies have investigated
the fundamental pathophysiological effects that lead to improve-
ment of renal disease in obese patients on low-calorie diets. Ix
and Sharma [44] investigated the effect of a low-calorie diet on
AMPK pathway activation and found that it reduced the fetuin-
A level, which led to an increase in the adiponectin level and sub-
sequently prevented the occurrence of podocyte injury. The ef-
fects of dietary modification on other adipokines and on the
secretion of fatty acids are additional areas of interest in the
study of obesity-related kidney disease [64].
Weight loss in patients with obesity and morbid obesity has
renal benefits. However, what is the most effective method for
maintaining weight loss over a long period of time?Many clinical
trials have demonstrated that low-calorie diets aid in weight loss
in obese patients, although these studies have failed to demon-
strate themaintenance of this weight loss over time and have re-
ported high dropout rates [65]. The use of anti-obesity agents
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in combination with low-calorie diets and exercise, has resulted
in modest decreases in weight and may cause significant side
effects, especially in patients with cardiovascular disease [42,
66]. The results of different studies examined in two meta-ana-
lyses [67, 68] that included 18 studies (assessingmedical and sur-
gical interventions) and 813 patients with differing degrees of
obesity have demonstrated that medical interventions for obes-
ity result in a reduction in proteinuria and glomerular filtration
rate stabilization. In contrast, surgery normalizes glomerular hy-
perfiltration and albuminuria, and encouraging data have been
reported indicating improved/stable renal function in some
patients with renal insufficiency who have undergone surgery
[67, 68]. Regarding morbid obesity, both medical treatments and
lifestyle changes have limited effects. In these patients, bariatric
surgery is the only treatment that has demonstrated efficacy in
maintaining long-term weight loss. In a recent study with a
median follow-up time of 4.4 years and 985 patients who under-
went bariatric surgery the authors observed that bariatric surgery
prevented the decline in renal function in MO patients [69]. In
addition, drastic weight loss secondary to bariatric surgery in
MO patients with ORG, normal preoperative renal function and
mild proteinuria resulted in excellent outcomes, as normal
renal function was maintained, blood pressure was improved
and albuminuria was attenuated after 10 years of follow-up
[36]. Although the surgical approach can reduce morbidity and
improve renal parameters in patients withmorbid obesity, baria-
tric surgery is associated with an increased risk of acute renal
failure postoperatively. This complication is associated with the
appearance of oxalate nephropathy but is rarely observed [70–72].
Drugs that inhibit the renin–angiotensin system have proved
useful for improving glomerularhyperfiltration in obese orMOpa-
tientswith renal disease by reducing the intracapillary glomerular
pressure and, consequently, podocyte injury and by enhancing
the attenuation of proteinuria [73]. Because hyperaldosteronism
promotes hyperfiltration and podocyte injury and mediates in-
flammation, the use of aldosterone inhibitors may be indicated
in patients with hyperaldosteronism, such as those with obesity
and obesity glomerulopathy. These drugs have renoprotective ef-
fects by blocking the fibrosis process that produces aldosterone
[46]. Notably, no studies have been performed on patients with
ORG. Further, the addition of aldosterone inhibitors to angioten-
sin-converting enzyme inhibitors or angiotensin II receptor block-
er treatments improves proteinuria but does not enhance renal
function. Given the scientific evidence regarding aldosterone inhi-
bitors, thesedrugs should be consideredas second-linedrugs, and
more studies demonstrating their efficacy should be conducted
[67]. In acomprehensive reviewof the roleof ectopic lipid accumu-
lation in obesity-related kidney disease, De Vries et al. [12] sug-
gested that this accumulation could represent a novel pathway
of this disease and that this information could facilitate the devel-
opment of new strategies for its treatment. In experimental mod-
els, interventions targeting cellular lipid metabolism have been
shown to decrease renal lipid accumulation and reduce glomeru-
lar injury [74, 75]; however, further investigation is needed to fully
understand what occurs in humans.
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